Dyslipidemias are defined as a wide range of abnormalities of the lipid profile. Treatment guidelines recommend aiming at lowering LDL-C. We investigated the adherence of Czech cardiologists to the dyslipidaemia treatment guidelines, especially in the management of patients with high and very high cardiovascular risk. In this retrospective cross-sectional multicentric study data from medical records of 450 adults with ASCVD, enrolled between June 2021 and January 2022, were analysed. Demographics, clinical outcomes, medical history, LLT treatment and other medications were collected. The physicians were to include patients at a very high risk of ASCVD and to complete a general questionnaire on their personal therapeutic preferences. Objectively assessed, only 80% of total patients (N = 450) enrolled in the study were at very high risk of ASCVD, and 12.7% of patients were at high risk of ASCVD, respectively. In total, 55 (13.1%) patients were diagnosed with familial hypercholesterolemia, and 39.1% of them had a positive family history of ASCVD. Generally, only 20.5% of patients reached the 2019 LDL-C goals- 19.4% of very high risk patients and 28.1% of high risk patients, respectively. 61% of the physicians preferred a slow and careful up-titration of the dose, which is contradictory to the guidelines. Only 17% of the physicians increased the statin dose or added/combined/changed the treatment to achieve the LDL-C goals as soon as possible. Surprisingly, in up to 61.5% of patients at very high risk who did not meet the LDL-C goals, their physicians stated subjective satisfaction with the treatment and considered no change needed. Among very high and high risk patients receiving lipid-lowering therapy, with high treatment adherence, the LDL-C goal attainment is very low and LLT utilization is rather sub-optimal. Improving observance of the guidelines by physicians bears a substantial potential for LDL-C goal attainment and thus improving overall benefit for patients for no additional costs.

3rd Department of Medicine General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

CEEOR Prague Czech Republic

Department of Biomedical Technology Czech Technical University Prague Prague Czech Republic

Department of Internal Medicine and Cardiology Faculty of Medicine Masaryk University University Hospital Brno Brno Czech Republic

Department of Neurology International Clinical Research Center St Anne's University Hospital Brno Czech Republic

Department of Neurology Mayo Clinic Rochester MN United States of America

See more in PubMed

Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al.. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. The Lancet. 2020;395: 795–808. doi: 10.1016/S0140-6736(19)32008-2 PubMed DOI PMC

Cicero AFG, Landolfo M, Ventura F, Borghi C. Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opin Pharmacother. 2019;20: 1277–1288. doi: 10.1080/14656566.2019.1604687 PubMed DOI

Kopin L, Lowenstein CJ. Dyslipidemia. Ann Intern Med. 2017;167: ITC81. doi: 10.7326/AITC201712050 PubMed DOI

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine. 2015;372: 2387–2397. doi: 10.1056/NEJMoa1410489 PubMed DOI

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al.. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine. 2015;372: 1489–1499. doi: 10.1056/NEJMoa1501031 PubMed DOI

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al.. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376: 1713–1722. doi: 10.1056/NEJMoa1615664 PubMed DOI

Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al.. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. Circulation. 2018;137: 1571–1582. doi: 10.1161/CIRCULATIONAHA.117.030950 PubMed DOI

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41: 111–188. doi: 10.1093/eurheartj/ehz455 PubMed DOI

Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al.. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DAVINCI study. Eur J Prev Cardiol. 2021;28: 1279–1289. doi: 10.1093/eurjpc/zwaa047 PubMed DOI

De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, et al.. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285: 135–146. doi: 10.1016/j.atherosclerosis.2019.03.014 PubMed DOI

Janský P, Rosolová H, Vrablík M. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa. 2017;59: e389–e415. doi: 10.1016/j.crvasa.2017.03.007 DOI

Vrablík M, Piťha J, Bláha V, Cífková R, Freiberger T, Karásek D, et al.. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. Cor Vasa. 2020;62: 185–197. doi: 10.33678/cor.2020.024 DOI

Šatný M, Tůmová E, Vrablík M, Mašková J, Laštůvka J. Studie LipitenCliDec-profil pacientů s nekontro-lovanou arteriální hypertenzí a/nebo dyslipidemií v primární péči v Česku: výsledky 2. fáze LipitenCliDec Study-the profile of patients with uncontrolled arterial hypertension and/or dyslipidemia in primary care in the Czech Republic: the 2 nd phase results. 2020. Available: www.atheroreview.eu

Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context. 2018;7. doi: 10.7573/dic.212534 PubMed DOI PMC

Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER). Am J Cardiol. 2010;105: 69–76. doi: 10.1016/j.amjcard.2009.08.651 PubMed DOI

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al.. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5: 941–950. doi: 10.1016/S2213-8587(17)30313-3 PubMed DOI

Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, et al.. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. Circulation. 2020;141: 1608–1617. doi: 10.1161/CIRCULATIONAHA.120.046524 PubMed DOI PMC

Ceska R, Latkovskis G, Ezhov M V., Freiberger T, Lalic K, Mitchenko O, et al.. The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. Current Atherosclerosis Reports. Current Medicine Group LLC 1; 2019. doi: 10.1007/s11883-019-0797-3 PubMed DOI PMC

Morieri ML, Perrone V, Veronesi C, Degli Esposti L, Andretta M, Plebani M, et al.. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes. Cardiovasc Diabetol. 2021;20: 144. doi: 10.1186/s12933-021-01338-y PubMed DOI PMC

Morieri ML, Lamacchia O, Manzato E, Giaccari A, Avogaro A, Amoresano L, et al.. Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes. Cardiovasc Diabetol. 2022;21: 57. doi: 10.1186/s12933-022-01495-8 PubMed DOI PMC

Mihaylova B. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet. 2012;380: 581–590. doi: 10.1016/S0140-6736(12)60367-5 PubMed DOI PMC

Rodriguez F., Maron D. J., Knowles J. W., Virani S. S., Lin S., & Heidenreich P. A. (2019). Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 4(3), 206. doi: 10.1001/jamacardio.2018.4936 PubMed DOI PMC